PAR · SAN.PA
Sanofi
€76.15+€0.64 (+0.85%)
Sanofi’s quoted price sits in the lower half of its reported 52-week range, 16.13% below the high.
Loading market information…
NASDAQ · FOCL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
EDAP TMS S.A. American Depositary Shares’s quoted price sits in the upper half of its reported 52-week range, 34.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
EDAP TMS S.A. American Depositary Shares’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.24. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow EDAP TMS S.A. American Depositary Shares’s reporting calendar.
THE COMPANY BEHIND THE TICKER
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $18.72M+18.35% vs estimate |
| Q1 2025 | May 15, 2025 | -$0.21-29.3% vs estimate | $15.17M-8.39% vs estimate |
|---|
| Q4 2024 | Mar 27, 2025 | -$0.05+50.23% vs estimate | $21.94M+5.2% vs estimate |
|---|
| Q2 2024 | Aug 28, 2024 | -$0.18-28.29% vs estimate | $17.58M+1.23% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $10.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€76.15+€0.64 (+0.85%)
Sanofi’s quoted price sits in the lower half of its reported 52-week range, 16.13% below the high.
€178.20+€0.50 (+0.28%)
EssilorLuxottica S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.97% below the high.
€228.40+€7.00 (+3.16%)
Sartorius Stedim Biotech S.A.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
€155.80+€2.90 (+1.9%)
Ipsen S.A.’s quoted price sits in the upper half of its reported 52-week range, 10.46% below the high.
€90.15-€0.85 (-0.93%)
bioMérieux S.A.’s quoted price sits in the lower half of its reported 52-week range, 22.35% below the high.
€81.10+€0.35 (+0.43%)
Abivax S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.65% below the high.
€344.50-€3.00 (-0.86%)
Virbac S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.55% below the high.
€10.43+€0.35 (+3.47%)
Emeis’s quoted price sits in the lower half of its reported 52-week range, 34.81% below the high.
